![]() |
|
|
Vol. 62, Issue 2, 304-312, August 2002
Institut National de la Santé et de la Recherche
Médicale (INSERM) E9910, Institut Claudius Régaud,
Toulouse, France (I.P., N.M., G.La., D.L.); Department of Clinical
Pharmacology, Rikshospitalet University Hospital, Oslo, Norway (G.Le.,
K.J.B.); L'École Pratique des Hautes Études/INSERM U517,
Mort Cellulaire et Cancer, UFR de Pharmacie, Dijon, France (A.B.); and
Service d'Hématologie, Centre Hospitalier Universitaire Purpan,
Toulouse, France (G.La.)
Previous studies have emphasized the role of glucosylceramide (Glu-Cer)
synthase in multidrug resistance (MDR) regulation. However, the
mechanism by which the inhibition of this enzyme results in increased
drug retention and cytotoxicity remains unclear. In this study, we
investigated the respective role of ceramide (Cer) accumulation and
Glu-Cer derivatives depletion in MDR reversal effect of
1-phenyl-2-decanoylamino-3-morpholino-1-propanolol (PDMP), a Glu-Cer
synthase inhibitor. We show here that treatment with PDMP resulted in
increased rhodamine 123 (Rh123) retention and potent chemosensitization
of P-glycoprotein (P-gp)-expressing cells, including KG1a cells,
KG1a/200 cells, K562/138 cells, and K562/mdr-1 cells. Metabolic studies
revealed that PDMP induced not only time-dependent Cer accumulation but
also reduction of all glycosylated forms of Cer, including Glu-Cer,
lactosylceramide (Lac-Cer), monosialo ganglioside (GM3) and disialo
ganglioside (GD3). The influence of these metabolites on P-gp function
was investigated by measuring Rh123 retention in PDMP-treated cells. P-gp function was found to be stimulated only by the addition of
gangliosides in all resistant cell lines, whereas Glu-Cer, Lac-Cer, and
Cer had no effect. Moreover, in KG1a/200 cells, GD3 and, to a lesser
extent, GM3 were found to phosphorylate P-gp on serine residues.
Altogether, these results suggest that, at least in leukemic cells,
gangliosides depletion accounts for PDMP-mediated MDR reversal effect,
and that gangliosides are important P-gp regulators perhaps through
their capacity to modulate P-gp phosphorylation.
This article has been cited by other articles:
![]() |
M. F. De Rosa, C. Ackerley, B. Wang, S. Ito, D. M. Clarke, and C. Lingwood Inhibition of Multidrug Resistance by AdamantylGb3, a Globotriaosylceramide Analog J. Biol. Chem., February 22, 2008; 283(8): 4501 - 4511. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-J. Dijkhuis, K. Klappe, W. Kamps, H. Sietsma, and J. W. Kok Gangliosides do not affect ABC transporter function in human neuroblastoma cells J. Lipid Res., June 1, 2006; 47(6): 1187 - 1195. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Gouaze, Y.-Y. Liu, C. S. Prickett, J. Y. Yu, A. E. Giuliano, and M. C. Cabot Glucosylceramide Synthase Blockade Down-Regulates P-Glycoprotein and Resensitizes Multidrug-Resistant Breast Cancer Cells to Anticancer Drugs Cancer Res., May 1, 2005; 65(9): 3861 - 3867. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Gouaze, J. Y. Yu, R. J. Bleicher, T.-Y. Han, Y.-Y. Liu, H. Wang, M. M. Gottesman, A. Bitterman, A. E. Giuliano, and M. C. Cabot Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy Mol. Cancer Ther., May 1, 2004; 3(5): 633 - 640. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Grazide, A.-D. Terrisse, S. Lerouge, G. Laurent, and J.-P. Jaffrezou Cytoprotective Effect of Glucosylceramide Synthase Inhibition against Daunorubicin-induced Apoptosis in Human Leukemic Cell Lines J. Biol. Chem., April 30, 2004; 279(18): 18256 - 18261. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. De Rosa, D. Sillence, C. Ackerley, and C. Lingwood Role of Multiple Drug Resistance Protein 1 in Neutral but Not Acidic Glycosphingolipid Biosynthesis J. Biol. Chem., February 27, 2004; 279(9): 7867 - 7876. [Abstract] [Full Text] [PDF] |
||||